Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Slides:



Advertisements
Similar presentations
Upfront Combination Therapy vs Step-Up Approach for PAH:
Advertisements

The Nurse View: Management of Pancreatic Cancer
Optimal Management of Spinal Muscular Atrophy
Program Goals. Program Goals Immunotherapy of B-cell Malignancies.
New ESMO Guidance on Tumor Sidedness in mCRC
NOACs In Long-term VTE Treatment: A State Of The Art Review
Post-autologous Transplant Therapy for Hodgkin Lymphoma
Optimizing Therapy for Osteoarthritis
Optimizing Use of Biological Agents in Ulcerative Colitis
Dry AMD and GA: The Present and Future
New Patient Journeys in Non-small cell lung cancer
What Comes Second?.
Advances in Dyslipidemia: What Have We Learned From ACC 2017
Neoadjuvant Therapy in HER2-Positive Breast Cancer
Surveying the Safety of NOACs in the Real World
Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma
A Focus on Polycythemia Vera for Nurse Practitioners and Physician Assistants.
Program Introduction. Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?
CDK4/6 Inhibitors in Practice
Updates in Lymphoma From Recent Congresses
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
The Biology Behind BCL2 as a Target in Myeloma
Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.
CD30 and Lymphoma: Pathology in Practice
Antithrombotic Protection in CAD and HF
Opportunities and Challenges in the Management of Advanced STS
A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma
Targeting BTK Signaling in B-Cell Malignancies
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
Oral Anticoagulation in AF
Understanding Comparative Effectiveness Data in Psoriatic Arthritis
Emerging Frontline Treatments for Patients With Hodgkin Lymphoma
Advancing the Treatment of IBD With Biologics
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
The Evolving Treatment Landscape in Atopic Dermatitis
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Treatment of Locally Advanced Pancreatic Cancer
Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Evaluating BTK Inhibitors in CLL
Are We Making Progress in the Management of Huntington Disease?
Proteasome Inhibitors and Patients
Challenges in LA SCCHN.
Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Introduction. Emerging Treatments for Thrombocytopenia in Adults With CLD Requiring Elective Invasive Procedures.
Reducing Risk for CV Outcomes
Improving Outcomes in Patients With SSc-ILD
The Patient With Early Stage MF-CTCL
A Multidisciplinary Perspective on the Management of Hypoparathyroidism.
Clinical Challenges and Updates in Managing Seizure Clusters
Practical Strategies for Getting Patients With Diabetes to Lipid Goal
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.
Cutaneous T-Cell Lymphoma: Disease, Diagnosis, and Therapy
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
AMD Therapy: Where Are We Now and Where Are We Going?
Optimizing Outcomes in Patients With NSCLC and Liver Metastases
Real-World Evidence.
A Closer Look.
Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.
MS, Age, and Immune Function
Next-Generation Sequencing and ctDNA
Anemia Explored.
Exploring the Use of Adeno-Associated Virus for Gene Therapy
PCSK9 Inhibitors and Real-World Evidence
Understanding the Role of Disability in MS Management
Selective Immunomodulation in MS
Patient Heterogeneity in CD
Presentation transcript:

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Introduction to CD30

Evaluation of CD30 Expression in Lymphomas

Pathology Report of CD30 Expression

Testing Methodology for CD30 Expression

CD30 Staining in pcALCL vs MF/SS

Issues Related to CD30-Negative Expression

CD30 Testing in Other Lymphoma Conditions

Therapeutic Approach for Patients With CD30-Positive MF/SS

Long-Term Management of Patients Receiving Systemic Therapies

ALCANZA Trial Study Design

ALCANZA Trial Efficacy

ALCANZA Trial Safety Profile

Treatment Strategy With BV

Factors to Consider in Optimizing Course of Treatment

MAVORIC Trial Study Design

MAVORIC Trial Patient Characteristics and Efficacy

ALCANZA vs MAVORIC

MAVORIC Trial Safety Profile

Potential Increase in GVHD in Patients With CTCL After Mogamulizumab Treatment

Ongoing Clinical Trials

Key Takeaways

Abbreviations

Abbreviations (cont)

Abbreviations (cont)